Roche said to have rekindled interest in BioMarin Pharmaceutical - sources

Swiss pharmaceuticals giant Roche has once again been studying a multi-billon dollar purchase of American rare disease specialist BioMarin Pharmaceutical, according to two sources familiar with the matter.

I understand that, so far, the majority of work and analysis on BioMarin has been carried out by Roche's own executives, led by Boris Zaitra, head of M&A...


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Wednesday, 6 July 2016, 12:00 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation